Medicare overspending on anemia drug
Washington Post, August 10, 2012
The U.S. health-care system is vastly overspending for a single anemia drug because Medicare overestimates its use by hundreds of millions of dollars a year, according to an analysis of federal data. The overpayment to hospitals and clinics arises because Medicare reimburses them based on estimates rather than the actual use of the drug.
Most Viewed
Most Emailed
- Patient Harm Data to Remain on Medicare's Hospital Compare Site
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Hard-Nosed About Physician Teamwork
- Quiet ORs Better for Patient Safety
- Building a Better Healthcare Board
- Case Study: Advance Care Conversations
- Tavenner Confirmed as CMS Administrator
- CMS Releases Hospital Pricing Data
- Access to EHR Notes Lauded by Patients, Providers
- Leapfrog Hospital Safety Scores 'Depressing'
